Theranexus SA (PA:ALTHX) — Market Cap & Net Worth
Market Cap & Net Worth: Theranexus SA (ALTHX)
Theranexus SA (PA:ALTHX) has a market capitalization of $57.91 Million (€49.53 Million) as of September 20, 2026. Listed on the PA stock exchange, this France-based company holds position #21446 globally and #333 in its home market, demonstrating a 1.48% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Theranexus SA's stock price €3.43 by its total outstanding shares 14441625 (14.44 Million). Also see balance sheet size of Theranexus SA for a full breakdown of the balance sheet.
Theranexus SA Market Cap History: 2017 to 2026
Theranexus SA's market capitalization history from 2017 to 2026. Data shows change from $250.72 Million to $57.91 Million (-15.67% CAGR). Also see Theranexus SA operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Theranexus SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Theranexus SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ALTHX stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
4.27x
Theranexus SA's market cap is 4.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $250.72 Million | $147.83K | -$2.11 Million | 1696.01x | N/A |
| 2018 | $302.56 Million | $110.93K | -$5.30 Million | 2727.49x | N/A |
| 2019 | $51.33 Million | $563.85K | -$5.58 Million | 91.03x | N/A |
| 2020 | $314.88 Million | $294.61K | -$4.80 Million | 1068.81x | N/A |
| 2021 | $83.57 Million | $602.00 | -$8.15 Million | 138828.40x | N/A |
| 2022 | $29.55 Million | $414.90K | -$6.57 Million | 71.21x | N/A |
| 2023 | $18.91 Million | $296.33K | -$6.83 Million | 63.81x | N/A |
| 2024 | $9.76 Million | $2.28 Million | -$1.77 Million | 4.27x | N/A |
Competitor Companies of ALTHX by Market Capitalization
Companies near Theranexus SA in the global market cap rankings as of September 20, 2026. Review ALTHX goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Theranexus SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Theranexus SA Historical Marketcap From 2017 to 2026
Between 2017 and today, Theranexus SA's market cap moved from $250.72 Million to $ 57.91 Million, with a yearly change of -15.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €57.91 Million | +60.28% |
| 2025 | €36.13 Million | +270.24% |
| 2024 | €9.76 Million | -48.39% |
| 2023 | €18.91 Million | -36.00% |
| 2022 | €29.55 Million | -64.65% |
| 2021 | €83.57 Million | -73.46% |
| 2020 | €314.88 Million | +513.49% |
| 2019 | €51.33 Million | -83.04% |
| 2018 | €302.56 Million | +20.67% |
| 2017 | €250.72 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Theranexus SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $57.91 Million USD |
| MoneyControl | $57.91 Million USD |
| MarketWatch | $57.91 Million USD |
| marketcap.company | $57.91 Million USD |
| Reuters | $57.91 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Theranexus SA
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonym… Read more